Combining Clinical and Genetic Data to Predict Response to Fingolimod Treatment in Relapsing Remitting Multiple Sclerosis Patients: A Precision Medicine Approach
Authors:
- Laura FerrèLFLaura Ferrè
- Ferdinando ClarelliFCFerdinando Clarelli
- Beatrice PignoletBPBeatrice Pignolet
- Elisabetta MasciaEMElisabetta Mascia
- Marco FrascaMFMarco Frasca
- Silvia SantoroSSSilvia Santoro
- Melissa SorosinaMSMelissa Sorosina
- Florence BucciarelliFBFlorence Bucciarelli
- Lucia MoiolaLMLucia Moiola
- Vittorio MartinelliVMVittorio Martinelli
- Giancarlo ComiGCGiancarlo Comi
- Roland LiblauRLRoland Liblau
Open Access
- 6 January 2023
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (1) , 122
Abstract
A personalized approach is strongly advocated for treatment selection in Multiple Sclerosis patients due to the high number of available drugs. Machine learning methods proved to be valuable tools in the context of precision medicine. In the present work, we applied machine learning methods to identify a combined clinical and genetic signature of response to fingolimod that could support the prediction of drug response. Two cohorts of fingolimod-treated patients from Italy and France were enrolled and divided into training, validation, and test set. Random forest training and robust feature selection were performed in the first two sets respectively, and the independent test set was used to evaluate model performance. A genetic-only model and a combined clinical–genetic model were obtained. Overall, 381 patients were classified according to the NEDA-3 criterion at 2 years; we identified a genetic model, including 123 SNPs, that was able to predict fingolimod response with an AUROC= 0.65 in the independent test set. When combining clinical data, the model accuracy increased to an AUROC= 0.71. Integrating clinical and genetic data by means of machine learning methods can help in the prediction of response to fingolimod, even though further studies are required to definitely extend this approach to clinical applicationsKeywords
Funding Information
- Fondazione Italiana Sclerosi Multipla (project 2013/R/13)
This publication has 40 references indexed in Scilit:
- Allelic Combinations of Immune-Response Genes Associated with Glatiramer Acetate Treatment Response in Russian Multiple Sclerosis PatientsPharmacogenomics, 2011
- Genome-wide association study of severity in multiple sclerosisGenes & Immunity, 2011
- Random Forests for Genetic Association StudiesStatistical Applications in Genetics and Molecular Biology, 2011
- CD46 in a Spanish cohort of multiple sclerosis patients: genetics, mRNA expression and response to interferon-beta treatmentMultiple Sclerosis Journal, 2010
- Predicting responders to therapies for multiple sclerosisNature Reviews Neurology, 2009
- Genome-wide Scan of 500 000 Single-Nucleotide Polymorphisms Among Responders and Nonresponders to Interferon Beta Therapy in Multiple SclerosisArchives of Neurology, 2009
- Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markersPharmacogenetics and Genomics, 2007
- HLA-DR2 Dose Effect on Susceptibility to Multiple Sclerosis and Influence on Disease CourseThe American Journal of Human Genetics, 2003
- Selection bias in gene extraction on the basis of microarray gene-expression dataProceedings of the National Academy of Sciences, 2002
- Interaction between HLA-DR2 and abnormal brain MRI in optic neuritis and early MSNeurology, 2000